Ruxolitinib + Panobinostat for Myelofibrosis

Recruiting in Palo Alto (17 mi)

+88 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Novartis Pharmaceuticals

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

Eligibility Criteria

This trial is for patients already enrolled in a Novartis or Incyte-sponsored study, receiving ruxolitinib alone or with panobinostat, and benefiting from it without progressive disease. They must have met all prior study requirements and shown compliance.

Inclusion Criteria

I am currently in a Novartis or Incyte study and meet all its requirements.

I am currently seeing positive results from my ruxolitinib treatment, alone or with panobinostat, and have followed all study requirements.

My condition hasn't worsened after treatment with ruxolitinib or its combination with panobinostat.

Participant Groups

The trial continues the use of ruxolitinib, either alone or combined with panobinostat, to assess long-term safety in treating conditions like Polycythemia Vera and Acute Myeloid Leukemia among others.

1Treatment groups

Experimental Treatment

Group I: Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combinationExperimental Treatment2 Interventions

All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.